Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Kevin Kalinsky, Seth A. Wander, Erika Hamilton et al.|Journal of Clinical Oncology|2024Cited by 75
Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cellsChun-Yu Liu, Ling‐Ming Tseng|PLoS ONE|2017Cited by 64